CSPC Pharmaceutical recombinant herpes zoster vaccine Sys6052 gets FDA clinical trial approval
CSPC Pharmaceutical Group Limited said its recombinant herpes zoster vaccine (Sys6052) obtained FDA clinical trial approval in the US.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Cspc Pharmaceutical's Recombinant Herpes Zoster Vaccine (Sys6052) Obtains FDA Clinical Trial Approval In U.S.
CSPC PHARMACEUTICAL GROUP LIMITED HKEX:1093